Related Experiment Video
Updated: Apr 15, 2026

Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling
Published on: February 5, 2019
Codeine should not be prescribed for breastfeeding mothers or children under the age of 12
Moran Lazaryan1, Chen Shasha-Zigelman1, Zachi Dagan2
1Pharmacy Department, Assaf Harofeh Medical Center, Zerifin, Sackler School of Medicine -Tel Aviv University, Tel-Aviv, Israel.
Insights
Codeine poses risks for children and breastfeeding mothers due to serious adverse events and uncertain effectiveness. Regulatory bodies now recommend against its use in these vulnerable populations.
Area of Science:
- Pharmacology and Toxicology
- Pediatric Medicine
- Maternal Health
Background:
- Regulatory authorities like the FDA and EMA have issued warnings concerning codeine use in pediatric patients and breastfeeding mothers.
- Codeine's safety and efficacy in these specific populations have been questioned, prompting a review of existing data.
Purpose of the Study:
- To explore the metabolic pathways and toxicological parameters of codeine in pediatric patients.
- To investigate the implications of codeine use in breastfeeding mothers, focusing on infant exposure and effects.
Main Methods:
- Systematic literature review of pharmacokinetic and pharmacodynamic studies.
- Analysis of case reports and post-marketing surveillance data on codeine-related adverse events.
- Evaluation of genetic polymorphisms affecting codeine metabolism.
Main Results:
- Codeine metabolism varies significantly in children, leading to unpredictable plasma concentrations.
- Serious adverse events, including respiratory depression, have been reported in pediatric populations.
- Codeine transfer into breast milk can result in infant exposure, with potential for adverse effects.
Conclusions:
- Given the risks of serious adverse events and questionable efficacy, codeine should not be prescribed for children under 12 years of age.
- Codeine use is not recommended for breastfeeding mothers due to potential risks to the infant.
Unlabelled:
Medical regulatory authorities, including the Food and Drug Administration and European Medicine Agency, have published restrictions regarding the use of codeine in paediatric patients and breastfeeding mothers. This review explored the various parameters that are involved in the metabolism and toxicology of codeine in these two populations.
Conclusion:
The growing volume of data on potential serious adverse events and questionable efficacy indicates that codeine should not be prescribed for children under 12 years of age and breastfeeding mothers.
Related Concept Videos
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Excretion
Factors Affecting Drug Response: Overview
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

